☰

Sucheta Telang - Publications

Affiliations: 
University of Louisville, Louisville, KY, United States 
Area:
Biochemistry, Molecular Biology
Tree Info Similar researchers PubMed Report error

50 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Lypova N, Telang S, Chesney J, Imbert-Fernandez Y. Increased 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 activity in response to EGFR signaling contributes to non-small cell lung cancer cell survival. The Journal of Biological Chemistry. PMID 31126985 DOI: 10.1074/Jbc.Ra119.007784  0.432
2018 Vanherwegen AS, Eelen G, Bomfim Ferreira G, Ghesquière B, Cook DP, Nikolic T, Roep B, Carmeliet P, Telang S, Mathieu C, Gysemans C. Vitamin D controls the capacity of human dendritic cells to induce functional regulatory T cells by regulation of glucose metabolism. The Journal of Steroid Biochemistry and Molecular Biology. PMID 30481575 DOI: 10.1016/J.Jsbmb.2018.11.011  0.369
2018 Mondal S, Roy D, Sarkar Bhattacharya S, Jin L, Jung D, Zhang S, Kalogera E, Staub J, Wang Y, Xuyang W, Khurana A, Chien J, Telang S, Chesney J, Tapolsky G, et al. Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers. International Journal of Cancer. PMID 30226266 DOI: 10.1002/Ijc.31868  0.516
2018 Chesney J, Imbert-Fernandez Y, Telang S, Baum M, Ranjan S, Fraig M, Batty N. Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors. Melanoma Research. PMID 29561296 DOI: 10.1097/Cmr.0000000000000444  0.315
2018 Chesney J, Mojesky A, Imbert-Fernandez Y, Trent J, Telang S. Abstract 5487: Targeting glycolysis for the treatment of cancer Cancer Research. 78: 5487-5487. DOI: 10.1158/1538-7445.Am2018-5487  0.534
2018 Imbert-Fernandez Y, Lanceta L, Telang S, Chesney J. Abstract 2305: Targeting 6-phosphofructo-2-kinase to increase the efficacy of ER and CDK4/6 inhibitors against breast cancer Cancer Research. 78: 2305-2305. DOI: 10.1158/1538-7445.Am2018-2305  0.431
2017 Grewal JS, Al-Rayyan N, Ritchie J, Schowe P, Falkner C, Telang S, Yaddanapudi K, Chesney JA. Targeting the glucose metabolism of monocytic myeloid-derived suppressor cells to stimulate cancer immunity. Journal of Clinical Oncology. 35: 126-126. DOI: 10.1200/Jco.2017.35.7_Suppl.126  0.463
2016 O'Neal J, Clem A, Reynolds L, Dougherty S, Imbert-Fernandez Y, Telang S, Chesney J, Clem BF. Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer. Breast Cancer Research and Treatment. PMID 27613609 DOI: 10.1007/S10549-016-3968-8  0.464
2016 Clem BF, O'Neal J, Klarer AC, Telang S, Chesney J. Clinical development of cancer therapeutics that target metabolism. Qjm : Monthly Journal of the Association of Physicians. 109: 367-72. PMID 26428335 DOI: 10.1093/Qjmed/Hcv181  0.761
2016 Chesney JA, Telang S, Yaddanapudi K, Grewal JS. Targeting 6-phosphofructo-2-kinase (PFKFB3) as an immunotherapeutic strategy. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E14548  0.449
2016 Telang S, Yaddanapudi K, Grewal J, Redman R, Fu S, Pohlmann P, Mahalingam D, Kurman M, Tapolsky G, Chesney J. Abstract B90: PFK-158 is a first-in-human inhibitor of PFKFB3 that selectively suppresses glucose metabolism of cancer cells and inhibits the immunosuppressive Th17 cells and MDSCs in advanced cancer patients Cancer Research. 76. DOI: 10.1158/1538-7445.Panca16-B90  0.549
2016 Imbert-Fernandez Y, Clem A, Clem B, Tapolsky G, Telang S, Chesney J. Abstract 56: Suppression of 6-Phosphofructo-2-Kinase (PFKFB3) for the treatment of breast cancer Cancer Research. 76: 56-56. DOI: 10.1158/1538-7445.Am2016-56  0.469
2016 Telang S, Yaddanadupi K, Tapolsky G, Redman R, Chesney J. Abstract 557: Taking the sweet out of Th17 cells to potentiate immuno-oncology drugs Cancer Research. 76: 557-557. DOI: 10.1158/1538-7445.Am2016-557  0.507
2015 Chesney J, Clark J, Lanceta L, Trent JO, Telang S. Targeting the sugar metabolism of tumors with a first-in-class 6-phosphofructo-2-kinase (PFKFB4) inhibitor. Oncotarget. 6: 18001-11. PMID 26221874 DOI: 10.18632/Oncotarget.4534  0.504
2015 Telang S, O'Neal J, Imbert-Fernandez Y, Clem B, Lypova N, Tapolsky GH, Trent J, Chesney J. Abstract 4478: 6-Phosphofructo-2-Kinase (PFKFB3): At the crossroads of resistance to targeted cancer therapies Cancer Research. 75: 4478-4478. DOI: 10.1158/1538-7445.Am2015-4478  0.474
2015 Mondal S, Roy D, Kalogera E, Khurana A, Tapolsky GH, Telang S, Chesney J, Shridhar V. Abstract 2706: Inhibition of PFKFB3/glycolysis overcomes chemoresistance in ovarian cancers Cancer Research. 75: 2706-2706. DOI: 10.1158/1538-7445.Am2015-2706  0.477
2014 Liu Y, Lu X, Huang L, Wang W, Jiang G, Dean KC, Clem B, Telang S, Jenson AB, Cuatrecasas M, Chesney J, Darling DS, Postigo A, Dean DC. Different thresholds of ZEB1 are required for Ras-mediated tumour initiation and metastasis. Nature Communications. 5: 5660. PMID 25434817 DOI: 10.1038/Ncomms6660  0.318
2014 Chesney J, Clark J, Klarer AC, Imbert-Fernandez Y, Lane AN, Telang S. Fructose-2,6-bisphosphate synthesis by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4) is required for the glycolytic response to hypoxia and tumor growth. Oncotarget. 5: 6670-86. PMID 25115398 DOI: 10.18632/Oncotarget.2213  0.782
2014 Yalcin A, Clem BF, Imbert-Fernandez Y, Ozcan SC, Peker S, O'Neal J, Klarer AC, Clem AL, Telang S, Chesney J. 6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27. Cell Death & Disease. 5: e1337. PMID 25032860 DOI: 10.1038/Cddis.2014.292  0.778
2014 Imbert-Fernandez Y, Clem BF, O'Neal J, Kerr DA, Spaulding R, Lanceta L, Clem AL, Telang S, Chesney J. Estradiol stimulates glucose metabolism via 6-phosphofructo-2-kinase (PFKFB3). The Journal of Biological Chemistry. 289: 9440-8. PMID 24515104 DOI: 10.1074/Jbc.M113.529990  0.443
2014 Klarer AC, O'Neal J, Imbert-Fernandez Y, Clem A, Ellis SR, Clark J, Clem B, Chesney J, Telang S. Inhibition of 6-phosphofructo-2-kinase (PFKFB3) induces autophagy as a survival mechanism. Cancer & Metabolism. 2: 2. PMID 24451478 DOI: 10.1186/2049-3002-2-2  0.776
2014 Liu Y, Sánchez-Tilló E, Lu X, Huang L, Clem B, Telang S, Jenson AB, Cuatrecasas M, Chesney J, Postigo A, Dean DC. The ZEB1 transcription factor acts in a negative feedback loop with miR200 downstream of Ras and Rb1 to regulate Bmi1 expression. The Journal of Biological Chemistry. 289: 4116-25. PMID 24371144 DOI: 10.1074/Jbc.M113.533505  0.398
2014 Clark J, Imbert-Fernandez Y, Chesney J, Telang S. The kinase domain of PFKFB4 is required to stimulate the glucose metabolism and growth of H460 xenografts Cancer and Metabolism. 2: 74. DOI: 10.1186/2049-3002-2-S1-P74  0.512
2014 Imbert-Fernandez Y, Telang S, Chesney J. Simultaneous inhibition of the estrogen receptor and 6-phosphofructo-2-kinase (PFKFB3) for the treatment of ER+ breast cancer Cancer and Metabolism. 2: 29. DOI: 10.1186/2049-3002-2-S1-P29  0.432
2014 Telang S, O’Neal J, Tapolsky G, Clem B, Kerr A, Imbert-Ferndandez Y, Chesney J. Discovery of a PFKFB3 inhibitor for phase I trial testing that synergizes with the B-Raf inhibitor vemurafenib Cancer and Metabolism. 2: 14. DOI: 10.1186/2049-3002-2-S1-P14  0.457
2014 Yalcin A, Imbert-Fernandez Y, Clem A, O’Neal J, Telang S, Clem B, Chesney J. Fructose-2,6-bisphosphate links glucose to survival and growth Cancer and Metabolism. 2: 1-1. DOI: 10.1186/2049-3002-2-S1-O5  0.458
2014 O'Neal J, Tapolsky G, Clem B, Telang S, Chesney J. Abstract 962: Identification of a PFKFB3 inhibitor suitable for phase I trial testing that synergizes with the B-Raf inhibitor vemurafenib Cancer Research. 74: 962-962. DOI: 10.1158/1538-7445.Am2014-962  0.488
2013 De Bock K, Georgiadou M, Schoors S, Kuchnio A, Wong BW, Cantelmo AR, Quaegebeur A, Ghesquière B, Cauwenberghs S, Eelen G, Phng LK, Betz I, Tembuyser B, Brepoels K, Welti J, ... ... Telang S, et al. Role of PFKFB3-driven glycolysis in vessel sprouting. Cell. 154: 651-63. PMID 23911327 DOI: 10.1016/J.Cell.2013.06.037  0.375
2013 Clem BF, O'Neal J, Tapolsky G, Clem AL, Imbert-Fernandez Y, Kerr DA, Klarer AC, Redman R, Miller DM, Trent JO, Telang S, Chesney J. Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer. Molecular Cancer Therapeutics. 12: 1461-70. PMID 23674815 DOI: 10.1158/1535-7163.Mct-13-0097  0.777
2013 Liu Y, Sánchez-Tilló E, Lu X, Huang L, Clem B, Telang S, Jenson AB, Cuatrecasas M, Chesney J, Postigo A, Dean DC. Sequential inductions of the ZEB1 transcription factor caused by mutation of Rb and then Ras proteins are required for tumor initiation and progression. The Journal of Biological Chemistry. 288: 11572-80. PMID 23443660 DOI: 10.1074/Jbc.M112.434951  0.377
2012 Telang S, Nelson KK, Siow DL, Yalcin A, Thornburg JM, Imbert-Fernandez Y, Klarer AC, Farghaly H, Clem BF, Eaton JW, Chesney J. Cytochrome c oxidase is activated by the oncoprotein Ras and is required for A549 lung adenocarcinoma growth. Molecular Cancer. 11: 60. PMID 22917272 DOI: 10.1186/1476-4598-11-60  0.731
2012 Telang S, Clem BF, Klarer AC, Clem AL, Trent JO, Bucala R, Chesney J. Small molecule inhibition of 6-phosphofructo-2-kinase suppresses t cell activation. Journal of Translational Medicine. 10: 95. PMID 22591674 DOI: 10.1186/1479-5876-10-95  0.774
2011 Chesney J, Rasku MA, Klarer AC, Miller DM, Telang S. Effect of denileukin diftitox on serum GM-CSF and clinical responses in stage IV melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2507. PMID 28022391 DOI: 10.1200/Jco.2011.29.15_Suppl.2507  0.743
2011 Telang S, Rasku MA, Clem AL, Carter K, Klarer AC, Badger WR, Milam RA, Rai SN, Pan J, Gragg H, Clem BF, McMasters KM, Miller DM, Chesney J. Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma. Bmc Cancer. 11: 515. PMID 22165955 DOI: 10.1186/1471-2407-11-515  0.735
2011 Natarajan N, Telang S, Miller D, Chesney J. Novel immunotherapeutic agents and small molecule antagonists of signalling kinases for the treatment of metastatic melanoma Drugs. 71: 1233-1250. PMID 21770473 DOI: 10.2165/11591380-000000000-00000  0.404
2011 Clem BF, Clem AL, Yalcin A, Goswami U, Arumugam S, Telang S, Trent JO, Chesney J. A novel small molecule antagonist of choline kinase-α that simultaneously suppresses MAPK and PI3K/AKT signaling. Oncogene. 30: 3370-80. PMID 21423211 DOI: 10.1038/Onc.2011.51  0.447
2011 Clem B, Tapolsky GH, O'Neal J, Chand P, Clem A, Trent J, Telang S, Chesney J. Abstract 2825: Characterization of a novel small molecule antagonist of 6-phosphofructo-2-kinase that suppresses glucose metabolism and tumor growth Cancer Research. 71: 2825-2825. DOI: 10.1158/1538-7445.Am2011-2825  0.54
2010 Yalcin A, Clem B, Makoni S, Clem A, Nelson K, Thornburg J, Siow D, Lane AN, Brock SE, Goswami U, Eaton JW, Telang S, Chesney J. Selective inhibition of choline kinase simultaneously attenuates MAPK and PI3K/AKT signaling. Oncogene. 29: 139-49. PMID 19855431 DOI: 10.1038/Onc.2009.317  0.346
2009 Yalcin A, Clem BF, Simmons A, Lane A, Nelson K, Clem AL, Brock E, Siow D, Wattenberg B, Telang S, Chesney J. Nuclear targeting of 6-phosphofructo-2-kinase (PFKFB3) increases proliferation via cyclin-dependent kinases. The Journal of Biological Chemistry. 284: 24223-32. PMID 19473963 DOI: 10.1074/Jbc.M109.016816  0.498
2009 Yalcin A, Telang S, Clem B, Chesney J. Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer. Experimental and Molecular Pathology. 86: 174-9. PMID 19454274 DOI: 10.1016/J.Yexmp.2009.01.003  0.532
2009 Liu Y, Clem B, Zuba-Surma EK, El-Naggar S, Telang S, Jenson AB, Wang Y, Shao H, Ratajczak MZ, Chesney J, Dean DC. Mouse fibroblasts lacking RB1 function form spheres and undergo reprogramming to a cancer stem cell phenotype. Cell Stem Cell. 4: 336-47. PMID 19341623 DOI: 10.1016/J.Stem.2009.02.015  0.407
2009 Clem B, Telang S, Clem A, Goswami U, Chesney J. Inhibition of 6-phosphofructo-2-kinase suppresses breast tumor growthin vivo. Cancer Research. 69: 3064. DOI: 10.1158/0008-5472.Sabcs-3064  0.477
2008 Thornburg JM, Nelson KK, Clem BF, Lane AN, Arumugam S, Simmons A, Eaton JW, Telang S, Chesney J. Targeting aspartate aminotransferase in breast cancer. Breast Cancer Research : Bcr. 10: R84. PMID 18922152 DOI: 10.1186/Bcr2154  0.44
2008 Rasku MA, Clem AL, Telang S, Taft B, Gettings K, Gragg H, Cramer D, Lear SC, McMasters KM, Miller DM, Chesney J. Transient T cell depletion causes regression of melanoma metastases. Journal of Translational Medicine. 6: 12. PMID 18334033 DOI: 10.1200/Jco.2008.26.15_Suppl.9030  0.363
2008 Clem B, Telang S, Clem A, Yalcin A, Meier J, Simmons A, Rasku MA, Arumugam S, Dean WL, Eaton J, Lane A, Trent JO, Chesney J. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Molecular Cancer Therapeutics. 7: 110-20. PMID 18202014 DOI: 10.1158/1535-7163.Mct-07-0482  0.527
2007 Telang S, Lane AN, Nelson KK, Arumugam S, Chesney J. The oncoprotein H-RasV12 increases mitochondrial metabolism. Molecular Cancer. 6: 77. PMID 18053146 DOI: 10.1186/1476-4598-6-77  0.388
2007 Telang S, Clem AL, Eaton JW, Chesney J. Depletion of ascorbic acid restricts angiogenesis and retards tumor growth in a mouse model Neoplasia. 9: 47-56. PMID 17325743 DOI: 10.1593/Neo.06664  0.32
2006 Telang S, Yalcin A, Clem AL, Bucala R, Lane AN, Eaton JW, Chesney J. Ras transformation requires metabolic control by 6-phosphofructo-2-kinase. Oncogene. 25: 7225-34. PMID 16715124 DOI: 10.1038/Sj.Onc.1209709  0.477
2006 Chesney J, Guarnaschelli J, Telang S, Miller D. DAB(389)IL2 (denileukin diftitox) suppresses growth of melanoma metastases Journal of Clinical Oncology. 24: 18010-18010. DOI: 10.1200/Jco.2006.24.18_Suppl.18010  0.399
2005 Chesney J, Telang S, Yalcin A, Clem A, Wallis N, Bucala R. Targeted disruption of inducible 6-phosphofructo-2-kinase results in embryonic lethality. Biochemical and Biophysical Research Communications. 331: 139-46. PMID 15845370 DOI: 10.1016/J.Bbrc.2005.02.193  0.378
Show low-probability matches.